Generic Medicine Info
Phaeochromocytoma, hyperthyroidism, uncorrected tachyarrhythmias or ventricular fibrillation. Concurrent use with cyclopropane and halogenated hydrocarbon anaesthetics.
Special Precautions
Patients with CV disease, cardiac arrythmias, occlusive vascular disease (e.g. atherosclerosis, arterial embolism, Raynaud's disease, cold injury, diabetic endarteritis, Buerger's disease), active myocardial ischaemia, post-myocardial infarction, electrolyte imbalance (e.g. hypokalaemia, hypomagnesemia). Correct hypovolaemia, hypoxia, hypercapnia, acidosis and electrolyte disturbances prior to initiation of therapy. Concomitant use with MAOIs. Infuse into a large vein to prevent extravasation. Pregnancy and lactation. Monitoring Parameters Monitor blood pressure, ECG, heart rate, cardiac output, pulmonary wedge pressure, serum glucose, renal function and urine output.
Adverse Reactions
Significant: Arrythmia, extravasation. Blood and lymphatic system disorders: Azotaemia. Cardiac disorders: Anginal pain, atrial fibrillation, bradycardia, palpitation, ectopic beats, tachycardia, ventricular conduction, widened QRS complex. Gastrointestinal disorders: Nausea, vomiting. Nervous system disorders: Headache. Psychiatric disorders: Anxiety. Respiratory, thoracic and mediastinal disorders: Dyspnoea. Skin and subcutaneous tissue disorders: Piloerection. Vascular disorders: Hypertension, hypotension.
Potentially Fatal: Rarely, ventricular arrythmia, gangrene (high dose).
Drug Interactions
Cardiac effects are antagonised by β-adrenergic agents (e.g. propanolol, metoprolol). α-adrenergic blocking agents may antagonise the vasoconstricting effect of high dose dopamine. Prolonged and enhanced effect with MAOIs. Risk of hypotension and bradycardia with phenytoin. May enhance effect of diuretics. Risk of excessive vasoconstriction with ergot alkaloids. May enhance vasopressor effect with TCAs and guanethidine.
CIMS Class
Cardiac Drugs
ATC Classification
C01CA04 - dopamine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of heart failure.
Disclaimer: This information is independently developed by CIMS based on dopamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in